Multicenter evaluation of a lateral-flow device test for diagnosing invasive pulmonary aspergillosis in ICU patients

Susanne Eigl, Juergen Prattes, Michaela Lackner, Birgit Willinger, Birgit Spiess, Mark Reinwald, Brigitte Selitsch, Michael Meilinger, Peter Neumeister, Frederike Reischies, Albert Wölfler, Reinhard B Raggam, Holger Flick, Stephan Eschertzhuber, Robert Krause, Dieter Buchheidt, Christopher R Thornton, Cornelia Lass-Flörl, Martin Hoenigl, Susanne Eigl, Juergen Prattes, Michaela Lackner, Birgit Willinger, Birgit Spiess, Mark Reinwald, Brigitte Selitsch, Michael Meilinger, Peter Neumeister, Frederike Reischies, Albert Wölfler, Reinhard B Raggam, Holger Flick, Stephan Eschertzhuber, Robert Krause, Dieter Buchheidt, Christopher R Thornton, Cornelia Lass-Flörl, Martin Hoenigl

Abstract

Introduction: The incidence of invasive pulmonary aspergillosis (IPA) in intensive care unit (ICU) patients is increasing, and early diagnosis of the disease and treatment with antifungal drugs is critical for patient survival. Serum biomarker tests for IPA typically give false-negative results in non-neutropenic patients, and galactomannan (GM) detection, the preferred diagnostic test for IPA using bronchoalveolar lavage (BAL), is often not readily available. Novel approaches to IPA detection in ICU patients are needed. In this multicenter study, we evaluated the performance of an Aspergillus lateral-flow device (LFD) test for BAL IPA detection in critically ill patients.

Methods: A total of 149 BAL samples from 133 ICU patients were included in this semiprospective study. Participating centers were the medical university hospitals of Graz, Vienna and Innsbruck in Austria and the University Hospital of Mannheim, Germany. Fungal infections were classified according to modified European Organization for Research and Treatment of Cancer/Mycoses Study Group criteria.

Results: Two patients (four BALs) had proven IPA, fourteen patients (sixteen BALs) had probable IPA, twenty patients (twenty-one BALs) had possible IPA and ninety-seven patients (one hundred eight BALs) did not fulfill IPA criteria. Sensitivity, specificity, negative predictive value, positive predictive value and diagnostic odds ratios for diagnosing proven and probable IPA using LFD tests of BAL were 80%, 81%, 96%, 44% and 17.6, respectively. Fungal BAL culture exhibited a sensitivity of 50% and a specificity of 85%.

Conclusion: LFD tests of BAL showed promising results for IPA diagnosis in ICU patients. Furthermore, the LFD test can be performed easily and provides rapid results. Therefore, it may be a reliable alternative for IPA diagnosis in ICU patients if GM results are not rapidly available.

Trial registration: ClinicalTrials.gov NCT02058316. Registered 20 January 2014.

References

    1. McNeil MM, Nash SL, Hajjeh RA, Phelan MA, Conn LA, Plikaytis BD, et al. Trends in mortality due to invasive mycotic diseases in the United States, 1980–1997. Clin Infect Dis. 2001;33:641–647. doi: 10.1086/322606.
    1. Patterson TF. Advances and challenges in management of invasive mycoses. Lancet. 2005;366:1013–1025. doi: 10.1016/S0140-6736(05)67381-3.
    1. Meersseman W, Lagrou K, Maertens J, Wilmer A, Hermans G, Vanderschueren S, et al. Galactomannan in bronchoalveolar lavage fluid: a tool for diagnosing aspergillosis in intensive care unit patients. Am J Respir Crit Care Med. 2008;177:27–34. doi: 10.1164/rccm.200704-606OC.
    1. Lugosi M, Alberti C, Zahar JR, Garrouste M, Lemiale V, Descorps-Desclère A, et al. Aspergillus in the lower respiratory tract of immunocompetent critically ill patients. J Infect. 2014;69:284–292. doi: 10.1016/j.jinf.2014.04.010.
    1. Baddley JW, Stephens JM, Ji X, Gao X, Schlamm HT, Tarallo M. Aspergillosis in intensive care unit (ICU) patients: epidemiology and economic outcomes. BMC Infect Dis. 2013;13:29. doi: 10.1186/1471-2334-13-29.
    1. Koulenti D, Garnacho-Montero J, Blot S. Approach to invasive pulmonary aspergillosis in critically ill patients. Curr Opin Infect Dis. 2014;27:174–183. doi: 10.1097/QCO.0000000000000043.
    1. Vandewoude K, Blot S, Benoit D, Depuydt P, Vogelaers D, Colardyn F. Invasive aspergillosis in critically ill patients: analysis of risk factors for acquisition and mortality. Acta Clin Belg. 2004;59:251–257. doi: 10.1179/acb.2004.037.
    1. Wauters J, Baar I, Meersseman P, Meersseman W, Dams K, De Paep R, et al. Invasive pulmonary aspergillosis is a frequent complication of critically ill H1N1 patients: a retrospective study. Intensive Care Med. 2012;38:1761–1768. doi: 10.1007/s00134-012-2673-2.
    1. Meersseman W, Vandecasteele SJ, Wilmer A, Verbeken E, Peetermans WE, Van Wijngaerden E. Invasive aspergillosis in critically ill patients without malignancy. Am J Respir Crit Care Med. 2004;170:621–625. doi: 10.1164/rccm.200401-093OC.
    1. Lass-Flörl C, Resch G, Nachbaur D, Mayr A, Gastl G, Auberger J, et al. The value of computed tomography-guided percutaneous lung biopsy for diagnosis of invasive fungal infection in immunocompromised patients. Clin Infect Dis. 2007;45:e101–e104. doi: 10.1086/521245.
    1. Meersseman W, Lagrou K, Maertens J, Van Wijngaerden E. Invasive aspergillosis in the intensive care unit. Clin Infect Dis. 2007;45:205–216. doi: 10.1086/518852.
    1. Marchetti O, Lamoth F, Mikulska M, Viscoli C, Verweij P, Bretagne S. European Conference on Infections in Leukemia (ECIL) Laboratory Working Groups. ECIL recommendations for the use of biological markers for the diagnosis of invasive fungal diseases in leukemic patients and hematopoietic SCT recipients. Bone Marrow Transplant. 2012;47:846–854. doi: 10.1038/bmt.2011.178.
    1. Bergeron A, Porcher R, Sulahian A, de Bazelaire C, Chagnon K, Raffoux E, et al. The strategy for the diagnosis of invasive pulmonary aspergillosis should depend on both the underlying condition and the leukocyte count of patients with hematologic malignancies. Blood. 2012;119:1831–1837. doi: 10.1182/blood-2011-04-351601.
    1. Hoenigl M, Salzer HJ, Raggam RB, Valentin T, Rohn A, Woelfler A, et al. Impact of galactomannan testing on the prevalence of invasive aspergillosis in patients with hematological malignancies. Med Mycol. 2012;50:266–269. doi: 10.3109/13693786.2011.603102.
    1. He H, Ding L, Sun B, Li F, Zhan Q. Role of galactomannan determinations in bronchoalveolar lavage fluid samples from critically ill patients with chronic obstructive pulmonary disease for the diagnosis of invasive pulmonary aspergillosis: a prospective study. Crit Care. 2012;16:R138. doi: 10.1186/cc11443.
    1. Husain S, Clancy CJ, Nguyen MH, Swartzentruber S, Leather H, LeMonte AM, et al. Performance characteristics of the Platelia Aspergillus enzyme immunoassay for detection of Aspergillus galactomannan antigen in bronchoalveolar lavage fluid. Clin Vaccine Immunol. 2008;15:1760–1763. doi: 10.1128/CVI.00226-08.
    1. Viscoli C, Machetti M, Gazzola P, De Maria A, Paola D, Van Lint MT, et al. Aspergillus galactomannan antigen in the cerebrospinal fluid of bone marrow transplant recipients with probable cerebral aspergillosis. J Clin Microbiol. 2002;40:1496–1499. doi: 10.1128/JCM.40.4.1496-1499.2002.
    1. Duettmann W, Koidl C, Troppan K, Seeber K, Buzina W, Wölfler A, et al. Serum and urine galactomannan testing for screening in patients with hematological malignancies. Med Mycol. 2014;52:647–652. doi: 10.1093/mmy/myu019.
    1. Patterson TF. Risk stratification for invasive aspergillosis: early assessment of host susceptibility. Med Mycol. 2009;47:S255–S260. doi: 10.1080/13693780902718339.
    1. Park SY, Lee SO, Choi SH, Sung H, Kim MN, Choi CM, et al. Aspergillus galactomannan antigen assay in bronchoalveolar lavage fluid for diagnosis of invasive pulmonary aspergillosis. J Infect. 2010;61:492–498. doi: 10.1016/j.jinf.2010.08.014.
    1. Aubry A, Porcher R, Bottero J, Touratier S, Leblanc T, Brethon B, et al. Occurrence and kinetics of false-positive Aspergillus galactomannan test results following treatment with β-lactam antibiotics in patients with hematological disorders. J Clin Microbiol. 2006;44:389–394. doi: 10.1128/JCM.44.2.389-394.2006.
    1. Affolter K, Tamm M, Jahn K, Halter J, Passweg J, Hirsch HH, et al. Galactomannan in bronchoalveolar lavage for diagnosing invasive fungal disease. Am J Respir Crit Care Med. 2014;190:309–317.
    1. Thornton CR. Development of an immunochromatographic lateral-flow device for rapid serodiagnosis of invasive aspergillosis. Clin Vaccine Immunol. 2008;15:1095–1105. doi: 10.1128/CVI.00068-08.
    1. Wiederhold NP, Thornton CR, Najvar LK, Kirkpatrick WR, Bocanegra R, Patterson TF. Comparison of lateral flow technology and galactomannan and (1→3)-β-d-glucan assays for detection of invasive pulmonary aspergillosis. Clin Vaccine Immunol. 2009;16:1844–1846. doi: 10.1128/CVI.00268-09.
    1. Wiederhold NP, Najvar LK, Bocanegra R, Kirkpatrick WR, Patterson TF, Thornton CR. Interlaboratory and interstudy reproducibility of a novel lateral-flow device and influence of antifungal therapy on detection of invasive pulmonary aspergillosis. J Clin Microbiol. 2013;51:459–465. doi: 10.1128/JCM.02142-12.
    1. Thornton C, Johnson G, Agrawal S. Detection of invasive pulmonary aspergillosis in haematological malignancy patients by using lateral-flow technology. J Vis Exp. 2012;61:3721.
    1. Hoenigl M, Koidl C, Duettmann W, Seeber K, Wagner J, Buzina W, et al. Bronchoalveolar lavage lateral-flow device test for invasive pulmonary aspergillosis diagnosis in haematological malignancy and solid organ transplant patients. J Infect. 2012;65:588–591. doi: 10.1016/j.jinf.2012.10.003.
    1. Willinger B, Lackner M, Lass-Flörl C, Prattes J, Posch V, Selitsch B, et al. Bronchoalveolar lavage lateral-flow device test for invasive pulmonary aspergillosis in solid organ transplant patients: a semiprospective multicenter study. Transplantation. 2014;98:898–902. doi: 10.1097/TP.0000000000000153.
    1. Hoenigl M, Prattes J, Spiess B, Wagner J, Prueller F, Raggam RB, et al. Performance of galactomannan, β-d-glucan, Aspergillus lateral-flow device, conventional culture, and PCR tests with bronchoalveolar lavage fluid for diagnosis of invasive pulmonary aspergillosis. J Clin Microbiol. 2014;52:2039–2045. doi: 10.1128/JCM.00467-14.
    1. Prattes J, Flick H, Prüller F, Koidl C, Raggam RB, Palfner M, et al. Novel tests for diagnosis of invasive aspergillosis in patients with underlying respiratory diseases. Am J Respir Crit Care Med. 2014;190:922–929. doi: 10.1164/rccm.201407-1275OC.
    1. Hoenigl M, Prattes J, Posch V, Duettmann W, Seeber K, Lackner M, et al. Diagnosing Invasive Pulmonary Aspergillosis in ICU patients: the role of Bronchoalveolar Lavage Lateral-Flow Device Test. 6th Advances Against Aspergillosis; 104:Poster number 7.
    1. Reischies, F; Prattes, J; Eigl, S; Lackner, M; Duettmann, W; Posch, V; et al. Bronchoalveolar Lavage Lateral-Flow Device Test for Diagnosing Invasive Pulmonary Aspergillosis in ICU and Haematological patients Mycoses. 2014;57:34–34
    1. Hoenigl M, Prattes J, Eigl S, Lass-Flörl C, Willinger B, Reischies F, et al. BRONCHOALVEOLAR LAVAGE LATERAL-FLOW DEVICE TEST FOR DIAGNOSING INVASIVE PULMONARY ASPERGILLOSIS IN ICU PATIENTS: A MULTICENTER STUDY. ID Week 2014, Abstract 1462, available under .
    1. De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis. 2008;46:1813–1821. doi: 10.1086/588660.
    1. Blot SI, Taccone FS, Van den Abeele AM, Bulpa P, Meersseman W, Brusselaers N, et al. A clinical algorithm to diagnose invasive pulmonary aspergillosis in critically ill patients. Am J Respir Crit Care Med. 2012;186:56–64. A published erratum appears in. Am J Respir Crit Care Med. 2012;186:808. doi: 10.1164/rccm.201111-1978OC.
    1. Vandewoude KH, Blot SI, Depuydt P, Benoit D, Temmerman W, Colardyn F, et al. Clinical relevance of Aspergillus isolation from respiratory tract samples in critically ill patients. Crit Care. 2006;10:R31. doi: 10.1186/cc4823.
    1. Montagna MT, Caggiano G, Lovero G, De Giglio O, Coretti C, Cuna T, et al. Epidemiology of invasive fungal infections in the intensive care unit: results of a multicenter Italian survey (AURORA Project) Infection. 2013;41:645–653. doi: 10.1007/s15010-013-0432-0.
    1. Tortorano AM, Dho G, Prigitano A, Breda G, Grancini A, Emmi V, et al. Invasive fungal infections in the intensive care unit: a multicentre, prospective, observational study in Italy (2006–2008) Mycoses. 2012;55:73–79. doi: 10.1111/j.1439-0507.2011.02044.x.
    1. Gustot T, Maillart E, Bocci M, Surin R, Trépo E, Degré D, et al. Invasive aspergillosis in patients with severe alcoholic hepatitis. J Hepatol. 2014;60:267–274. doi: 10.1016/j.jhep.2013.09.011.
    1. Held J, Schmidt T, Thornton CR, Kotter E, Bertz H. Comparison of a novel Aspergillus lateral-flow device and the Platelia galactomannan assay for the diagnosis of invasive aspergillosis following haematopoietic stem cell transplantation. Infection. 2013;41:1163–1169. doi: 10.1007/s15010-013-0472-5.
    1. Luong ML, Clancy CJ, Vadnerkar A, Kwak EJ, Silveira FP, Wissel MC, et al. Comparison of an Aspergillus real-time polymerase chain reaction assay with galactomannan testing of bronchoalveolar lavage fluid for the diagnosis of invasive pulmonary aspergillosis in lung transplant recipients. Clin Infect Dis. 2011;52:1218–1226. doi: 10.1093/cid/cir185.
    1. Azoulay E, Dupont H, Tabah A, Lortholary O, Stahl JP, Francais A, et al. Systemic antifungal therapy in critically ill patients without invasive fungal infection. Crit Care Med. 2012;40:813–822. doi: 10.1097/CCM.0b013e318236f297.
    1. Spiess B, Postina P, Reinwald M, Cornely OA, Hamprecht A, Hoenigl M, et al. Incidence of cyp51 A key mutations in Aspergillus fumigatus—a study on primary clinical samples of immunocompromised patients in the period of 1995–2013. PLoS One. 2014;9 doi: 10.1371/journal.pone.0103113.
    1. Prattes J, Koidl C, Eigl S, Krause R, Hoenigl M. Bronchoalveolar lavage fluid sample pretreatment with Sputasol significantly reduces galactomannan levels. J Infect. 2015;70:541–543. doi: 10.1016/j.jinf.2014.11.005.
    1. Escribano P, Marcos-Zambrano LJ, Peláez P, Muñoz P, Padilla B, Bouza E, et al. Sputum and bronchial secretion samples are equally useful as bronchoalveolar lavage samples for the diagnosis of invasive pulmonary aspergillosis in selected patients. Med Mycol. 2015;53:235–240. doi: 10.1093/mmy/myu090.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever